159 related articles for article (PubMed ID: 33129922)
1. Tumor mutation burden in blood predicts benefit from neoadjuvant chemo/radiotherapy in locally advanced rectal cancer.
Ji D; Zhang D; Zhan T; Jia J; Han W; Li Z; Li M; Song C; Wang J; Gu J
Genomics; 2021 Jan; 113(1 Pt 2):957-966. PubMed ID: 33129922
[TBL] [Abstract][Full Text] [Related]
2. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study.
Zhou J; Wang C; Lin G; Xiao Y; Jia W; Xiao G; Liu Q; Wu B; Wu A; Qiu H; Zhang F; Hu K; Xue H; Shen Z; Wang Z; Han J; Niu B; Xu Y; Yu Z; Yang L
Clin Cancer Res; 2021 Jan; 27(1):301-310. PubMed ID: 33046514
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis.
Chang L; Zhang X; He L; Ma Q; Fang T; Jiang C; Ma Z; Li Q; Wu C; Tao J
Oncologist; 2023 Dec; 28(12):e1198-e1208. PubMed ID: 37294663
[TBL] [Abstract][Full Text] [Related]
4. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
5. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer.
Schou JV; Larsen FO; Sørensen BS; Abrantes R; Boysen AK; Johansen JS; Jensen BV; Nielsen DL; Spindler KL
Ann Oncol; 2018 Mar; 29(3):610-615. PubMed ID: 29253083
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
7. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.
Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P
Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer.
McDuff SGR; Hardiman KM; Ulintz PJ; Parikh AR; Zheng H; Kim DW; Lennerz JK; Hazar-Rethinam M; Van Seventer EE; Fetter IJ; Nadres B; Eyler CE; Ryan DP; Weekes CD; Clark JW; Cusack JC; Goyal L; Zhu AX; Wo JY; Blaszkowsky LS; Allen J; Corcoran RB; Hong TS
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250394
[TBL] [Abstract][Full Text] [Related]
9. Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy.
Ji D; Yi H; Zhang D; Zhan T; Li Z; Li M; Jia J; Qiao M; Xia J; Zhai Z; Song C; Gu J
Cancer Immunol Res; 2018 Nov; 6(11):1401-1416. PubMed ID: 30282671
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer: Secondary Analysis of a Randomized Trial.
Appelt AL; Andersen RF; Lindebjerg J; Jakobsen A
Am J Clin Oncol; 2020 Jan; 43(1):9-13. PubMed ID: 31569168
[TBL] [Abstract][Full Text] [Related]
11. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
[TBL] [Abstract][Full Text] [Related]
12. Rectal cancer sub-clones respond differentially to neoadjuvant therapy.
Frydrych LM; Ulintz P; Bankhead A; Sifuentes C; Greenson J; Maguire L; Irwin R; Fearon ER; Hardiman KM
Neoplasia; 2019 Oct; 21(10):1051-1062. PubMed ID: 31521947
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of changes in the level of carbohydrate antigen 19-9 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Zheng Z; Wang X; Huang Y; Lu X; Chi P
Colorectal Dis; 2020 Dec; 22(12):2068-2077. PubMed ID: 32936987
[TBL] [Abstract][Full Text] [Related]
14. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.
Eyck BM; Jansen MP; Noordman BJ; Atmodimedjo PN; van der Wilk BJ; Martens JW; Helmijr JA; Beaufort CM; Mostert B; Doukas M; Wijnhoven BP; Lagarde SM; van Lanschot JJB; Dinjens WN
J Pathol; 2023 Jan; 259(1):35-45. PubMed ID: 36196486
[TBL] [Abstract][Full Text] [Related]
15. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.
Khakoo S; Carter PD; Brown G; Valeri N; Picchia S; Bali MA; Shaikh R; Jones T; Begum R; Rana I; Wotherspoon A; Terlizzo M; von Loga K; Kalaitzaki E; Saffery C; Watkins D; Tait D; Chau I; Starling N; Hubank M; Cunningham D
Clin Cancer Res; 2020 Jan; 26(1):183-192. PubMed ID: 31852830
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
17. Prognostic significance of carcinoembryonic antigen combined with carbohydrate antigen 19-9 following neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
Zheng Z; Wang X; Lu X; Huang Y; Chi P
Colorectal Dis; 2021 Sep; 23(9):2320-2330. PubMed ID: 33900006
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor DNA detection after neoadjuvant treatment and surgery predicts recurrence in patients with early-stage and locally advanced rectal cancer.
Hofste LSM; Geerlings MJ; von Rhein D; Rütten H; Westenberg AH; Weiss MM; Gilissen C; Hofste T; van der Post RS; Klarenbeek BR; de Wilt JHW; Ligtenberg MJL;
Eur J Surg Oncol; 2023 Jul; 49(7):1283-1290. PubMed ID: 36740555
[TBL] [Abstract][Full Text] [Related]
20. GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer.
Zhu K; Zhao Q; Yue J; Shi P; Yan H; Xu X; Wang R
Oncotarget; 2016 Oct; 7(42):68328-68338. PubMed ID: 27634904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
